Increased risk of comorbid rheumatic disorders in vitiligo patients: A nationwide population‐based study. Issue 8 (31st March 2017)

• Record Type: Journal Article
• Authors: Choi, Chong Won; Eun, Sung Hye; Choi, Kwang Hyun; Bae, Jung Min
• Is Part Of: Journal of dermatology. Volume 44:Issue 8(2017)
• Page Start: 909
• Page End: 913
• Publication Date: 2017-03-31
• Subjects: comorbidity -- epidemiology -- nationwide population‐based study -- rheumatic disorder -- vitiligo; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.13846
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: Vitiligo is a common acquired depigmentation disorder. Previous studies have shown that vitiligo is associated with a variety of autoimmune disorders. However, a large‐scale epidemiological study focused on comorbid rheumatic disorders has not been undertaken. To clarify the associations between vitiligo and various rheumatic disorders, we performed a cross‐sectional study using data from the Korean National Health Insurance claims database. Between 2009 and 2013, totals of 86 210 patients with vitiligo and 172 420 age‐ and sex‐matched controls without vitiligo were enrolled in this study. Vitiligo patients were found to be at increased risk of systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome and rheumatoid arthritis, but no significant association was found between vitiligo and dermatomyositis/polymyositis, Behçet's disease or ankylosing spondylitis. Subgroup analysis showed an increased risk of dermatomyositis/polymyositis in male and ankylosing spondylitis in female vitiligo patients. The risks of dermatomyositis/polymyositis or ankylosing spondylitis were higher in young vitiligo patients. Our study confirms a significant association between vitiligo and rheumatic disorders. Differences in comorbid rheumatic disorders by age group and sex suggest the need for patient‐specific approaches. Careful consideration of rheumatic disorders is required for the proper management of comorbidities in vitiligo patients.